CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ: SYRS) announced today that its management team will participate in the upcoming Morgan Stanley Global Healthcare Conference. Details are as follows:
Morgan Stanley Global Healthcare Conference
Date: Wednesday,
September 14
Location: Grand Hyatt New York, 109 East 42nd
Street, New York, NY
About Syros Pharmaceuticals
Syros Pharmaceuticals is
pioneering the understanding of the non-coding region of the genome to
advance a new wave of medicines that control expression of
disease-driving genes. Syros has built a proprietary platform to
systematically and efficiently analyze this unexploited region of DNA in
human disease tissue to identify and drug novel targets linked to
genomically defined patient populations. Because gene expression is
fundamental to the function of all cells, the Company’s gene control
platform has broad potential to achieve profound and durable benefit
across a range of diseases. Syros is focused on cancer and
immune-mediated diseases and is advancing a growing pipeline, including
its lead drug candidates SY-1425, a selective RARα agonist for
genomically defined subsets of patients identified by its platform, for
a range of cancers including acute myeloid leukemia and myelodysplastic
syndrome, and SY-1365, a selective CDK7 inhibitor for a range of blood
cancers and solid tumors. Led by a team with deep experience in drug
discovery, development and commercialization, Syros is located in
Cambridge, Mass.